KAPPA-PVIIA

Information

• Research Project
• 6210884

• ApplicationId

  6210884

• Core Project Number

  R43HL065793

• Full Project Number

  1R43HL065793-01

• Serial Number

  65793

• FOA Number

• Sub Project Id

• Project Start Date

  9/25/2000 - 24 years ago

• Project End Date

  3/24/2002 - 22 years ago

• Program Officer Name

• Budget Start Date

  9/25/2000 - 24 years ago

• Budget End Date

  3/24/2002 - 22 years ago

• Fiscal Year

  2000

• Support Year

  1

• Suffix

• Award Notice Date

  9/25/2000 - 24 years ago

Organizations

• COGNETIX, INC.

The primary aim of this proposal is to determine the potential of the Conus peptide Kappa-PVIIA as therapeutic. As a first step in determining the therapeutic potential of Kappa-PVIIA we intend to examine the ability of the peptide to protect excised rabbit hearts against periods of oxygen depletion. Based on the results of this study the experiments will be repeated in an anesthetized rabbit model. In addition the stability of the peptide in solution will be assessed at different temperatures. In phase II we propose to carry out further in vivo characterization of kappa-PVIIA in animal models that more closely mimic human disease conditions. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name

• Activity

  R43

• Administering IC

  HL

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  99748

• Sub Project Total Cost

• ARRA Funded

• CFDA Code

  837

• Ed Inst. Type

• Funding ICs

  NHLBI:99748\

• Funding Mechanism

• Study Section

  ZRG1

• Study Section Name

  Special Emphasis Panel

• Organization Name

  COGNETIX, INC.

• Organization Department

• Organization DUNS

• Organization City

  SALT LAKE CITY

• Organization State

  UT

• Organization Country

  UNITED STATES

• Organization Zip Code

  84108

• Organization District

  UNITED STATES